A randomized clinical trial to compare the effectiveness of oral contraceptives containing levonorgestrel, desogestrel, cyproterone acetate, and drospirenone on levels of adipokines, and adiposity indices in women with polycystic ovary syndrome.

To compare the effects of oral contraceptives containing levonorgestrel (LNG), desogestrel (DSG), Cyproterone Acetate (CPA), and drospirenone on serum adipokines including adiponectin, leptin and resistin in patients with polycystic ovarian syndrome (PCOS ).

This study is a randomized single blinded parallel clinical trial. Sample size is estimated as 80 person. This clinical trial is placed in phase 3 of clinical trials.

This randomized clinical trial will be done in the Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Present study will be done single-blind in which outcome assessor will be kept blind and won’t be aware of the type of drug that the patients will receive.

Inclusion criteria: presence of diagnostic criteria for polycystic ovary syndrome based on the Androgen Excess and PCOS Society (AES); ages 18 to 45 years. Exclusion criteria: Pregnancy; Use of hormone drugs, anti-androgens and insulin sensitizers for at least three months; Smoking; Obesity; Chronic medical disorders; Serious side effects such as thrombosis.

Intervention Group 1: Oral contraceptives (OCs) containing Levonorgestrel. Intervention Group 2: OCs containing Desogestrel. Intervention Group 3: OCs containing Cyproterone Acetate. Intervention Group 4: OCs containing Drospirenone.

Adiponectin; leptin; resistin.

A blocking or stratification random allocation (block size = 4), using a computer-based random number generator will be prepared to assign participants to treatment groups. The randomization sequence will be prepared before the trial, initiated by an independent statistician.

Both the clinical examiner and data analyst are blinded to the intervention each patient receives during the trial. For this purpose, before beginning the study, a person outside the research team who knew the interventions, assigned patients to treatment groups. Hence, only this person was aware of the treatment in each group.

َAfter completion of the study, part of the data, such as information about the main outcomes will be shared.

Starting availability of data is 6 months after publishing the results.

The data of this study will be available to all medical science researchers.

Researchers are only permitted to use the above study information as descriptive analysis or as part of a meta-analysis.

Applicants can contact Dr. Mina Amiri, Academic Member of the University of Medical Sciences, through the following address, contact number and email: Address: No 24, Institute of Endocrinology and Metabolism, Aarabi street, Yemen street, Velenjak. Phone: 00982122432569 Postcode: 1985717413 Email: mina_amiri_p@yahoo.com

1- Submit a request to access the data file by email 2. Submission of a formal application form for the relevant research project and the need for the above study data by the applicants: This form should only be issued through accredited research bodies. 3- Applicant's visit to Shahid Beheshti Institute of Endocrinology and Metabolism Research Institute to complete consent form to comply with ethical obligations required to use data 4- Investigating the Applicants' Application in the Scientific Committee of the Endocrinology Institute and Deciding to Submit Data as Non-Identifiable Study Participants (Maximum Within One Month) 5- Send study data to researcher's email 6. Monitor how data is used

Not comment.